James R. McNab - 28 Jan 2022 Form 4 Insider Report for TITAN PHARMACEUTICALS INC (TTNP)

Reporting relationship: Director
Issuer ticker: TTNP
Reported as of: 28 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jan 2022, 14:14:28 UTC
Prior SEC filing: 05 Jan 2022
Source filing: View source filing
Reporting owner signature: /S/ James R. McNab

Key filing fact

James R. McNab filed Form 4 for TITAN PHARMACEUTICALS INC (TTNP) on 28 Jan 2022.

Key facts

This page summarizes James R. McNab's Form 4 filing for TITAN PHARMACEUTICALS INC (TTNP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Jan 2022, 14:14.

Change

Previous filing in this sequence was filed on 05 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TTNP transaction

Common Stock

Other

Transaction value
Shares: +51,021
Change %
Price
Shares after: 51,021
Date: 28 Jan 2022
Ownership: By JT Pharma
Footnotes: F1

TTNP holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,669
Date: 28 Jan 2022
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents $50,000 of shares issued to JT Pharmaceuticals, Inc. ("JT") as a milestone payment under the October 2020 asset purchase agreement. Mr. McNab is a principal of JT and has voting and dispositive control of such shares.